Maxwell J Lasko1, David P Nicolau2,3. 1. Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT, 06102, USA. 2. Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT, 06102, USA. david.nicolau@hhchealth.org. 3. Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA. david.nicolau@hhchealth.org.
Abstract
PURPOSE OF REVIEW: Gram-negative resistance is a growing concern globally. Enterobacterales, formerly Enterobacteriaceae, have developed resistance mechanisms to carbapenems that leave very few antimicrobial options in the clinician's armamentarium. RECENT FINDINGS: New antimicrobials like ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and plazomicin have the potential to overcome resistance mechanisms in Enterobacterales including different classes of carbapenemases. Novel β-lactam/β-lactamase inhibitors, plazomicin, and cefiderocol give the clinician options that were once not available. Utilizing these options is of the utmost importance when treating carbapenem-resistant Enterobacterales.
PURPOSE OF REVIEW: Gram-negative resistance is a growing concern globally. Enterobacterales, formerly Enterobacteriaceae, have developed resistance mechanisms to carbapenems that leave very few antimicrobial options in the clinician's armamentarium. RECENT FINDINGS: New antimicrobials like ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and plazomicin have the potential to overcome resistance mechanisms in Enterobacterales including different classes of carbapenemases. Novel β-lactam/β-lactamase inhibitors, plazomicin, and cefiderocol give the clinician options that were once not available. Utilizing these options is of the utmost importance when treating carbapenem-resistant Enterobacterales.
Authors: Simon Portsmouth; David van Veenhuyzen; Roger Echols; Mitsuaki Machida; Juan Camilo Arjona Ferreira; Mari Ariyasu; Peter Tenke; Tsutae Den Nagata Journal: Lancet Infect Dis Date: 2018-10-25 Impact factor: 25.071
Authors: Sibylle H Lob; Meredith A Hackel; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; James A Karlowsky; Daniel F Sahm Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Francesco Colombo; Ali Waheed; Sandro Panese; Claudio Scarparo; Maria Solinas; Saverio Giuseppe Parisi; Nicholas Geremia Journal: Infez Med Date: 2022-09-01
Authors: Laurine S Blanchard; Alex Van Belkum; Dominique Dechaume; Thomas P Armstrong; Christopher L Emery; Yun X Ying; Michael Kresken; Marion Pompilio; Diane Halimi; Gilles Zambardi Journal: J Clin Microbiol Date: 2021-11-10 Impact factor: 5.948
Authors: Ashlan J Kunz Coyne; Anthony M Casapao; Carmen Isache; James Morales; Yvette S McCarter; Christopher A Jankowski Journal: Microbiol Spectr Date: 2021-10-27
Authors: Phillip E Klebba; Salete M C Newton; David A Six; Ashish Kumar; Taihao Yang; Brittany L Nairn; Colton Munger; Somnath Chakravorty Journal: Chem Rev Date: 2021-03-16 Impact factor: 60.622